Scientists from the Saint Petersburg Scientific Research Institute of Phthisiopulmonology and the Research Institute of Influenza have developed new vaccines against tuberculosis. According to the director of the St. Petersburg Research Institute of Physics, Peter Yablonsky, two developments are ready for clinical trials: parenteral and nasal prophylactic drugs.
“We have already passed all the experimental phases, now an agreement is being discussed at the level of the union state with the participation of Kazakhstan and Belarus in order to receive fairly serious funding, and it will be launched into series upon completion of work. I hope that in the next year or two we will know the results of the third phase of clinical trials,” he said.
The scientist clarified that the new vaccines will be aimed primarily at producing antibodies in patients, thereby “accustoming” the body to a possible encounter with mycobacterium tuberculosis and to their further neutralization.
